Ari D. Panzer, BS
Articles
April 12th 2022
Patients’ Access to 2018 FDA-Approved Drugs 1 Year Post Approval
Ari D. Panzer, BS Nikoletta M. Margaretos, BA Naomi Bridger, BS Mikala C. Osani, MPH Rachel C. Lai, MPH James D. Chambers, PhD
2018 was a landmark year for new drug approvals. However, patients’ access to these novel drugs varied by drug category and enrolled health plan.
October 8th 2019
Variation in US Private Health Plans’ Coverage of Orphan Drugs
James D. Chambers, PhD Ari D. Panzer, BS David D. Kim, PhD Nikoletta M. Margaretos, BA Peter J. Neumann, ScD
Health plans restrict orphan drug coverage less often than nonorphan drug coverage. However, the frequency of restrictions varies considerably across plans.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024
